> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# An update from David Lawson, Director of Medical Technology and Innovation at the Department for Health & Social Care (DHSC)
- URL: https://med-techinsights.com/an-update-from-david-lawson-director-of-medical-technology-and-innovation-at-the-department-for-health-social-care-dhsc/
- Published: 2026-11-20T08:35:58.000Z
- Updated: 2026-11-20T08:35:58.000Z
- Author: Barbara Harpham
- Tags: Policy & Regulation

***From value based procurement to the proposed innovator passports, it’s been a busy year for policy and medical technology. The MTG sat down with David Lawson to discuss the work being done to implement this across the NHS.***

---

***MTG: The value based-procurement guidance was published in June, can you update us on how it has been taken up across the NHS, and what you are focusing on to support wider use?***

DL: We recognise that publishing the guidance is only the first step and in July we set out our implementation plans which centre on three core workstreams: monitoring, evaluation and learning, training and promoting uptake. 

We have commissioned the NHS Strategy Unit to conduct a three-year evaluation of the policy, including measuring uptake by national framework providers and NHS Trusts. The first report will be published next spring. The team are also working closely with colleagues in the Devolved Governments to share learning and support each other to apply VBP across the whole of the UK. 

To support training we are commissioning on-line training for NHS procurement teams on the key principles of VBP and how to apply the VBP guidance in practice. This training will complement an introductory training module which has already been made available via the NHS Centre for Commercial Excellence Applied Learning.

To promote uptake, we have established a network of VBP Champions drawn from NHS Trust procurement teams, the first meeting of which took place in September 2026\. The Champions Network will promote uptake of the VBP guidance in local procurement organisations. A director-level sponsor and working-level manager will be responsible for conducting at least one procurement using the guidance and will share their learnings via interviews and case studies.

Over the last 12 months we have made good progress in moving the debate on VBP from individual case study examples to the routine application of VBP for all medtech procurement. The challenge over the next 12 months is to build knowledge and confidence in applying VBP to drive decision-making.

***MTG: The Innovator Passport was announced as a way to end repeated assessments across trusts. Where has work on this and the MedTech Compass got to, and what do suppliers need to know in the year ahead?***

DL: Innovators face differing local evidence standards and a complex, non-linear route into the NHS, while both industry and the NHS can lack knowledge and understanding of assurance requirements. 

The Innovator Passport will tackle these challenges by reducing unnecessary duplication in assurance, enabling reuse of core evidence from trusted sources, and providing clearer, more consistent expectations for local requirements.

By the end of December 2026, we will publish a peer learning publication on more efficient approaches to undertaking data protection impact assessments (DPIAs), identified by industry as the most burdensome check for digital technologies. It will showcase promising practice and inform further testing to drive greater consistency across the NHS. We will also be launching the first part of a new digital system to speed up decision-making by surfacing trusted information on all medical devices in one place. 

This will be followed next spring with a workflow assurance system to help both NHS organisations and suppliers speed up the completion of local risk checks by designing out the need to submit the same information multiple times in different formats. Webinars will be held in December to introduce the peer learning publication and demo the new system. 

Our ambition is that through the implementation of practical tools for NHS organisations to use, we speed up decision-making. In the same way that we now have targets for clinical trials, we intend to set targets for completion of local risk checks and use the new system to track our progress.

***MTG: The proposed abolition of NHS England means we are seeing a lot of reorganisation of the centre at the moment. What work is being done at the Department to ensure the patient voice is involved with decisions concerning medical technology?***

DL: We have worked hard to ensure the voice of the patient is at the heart of decision-making. Throughout the reform of the Part IX drug tariff, which controls the £1.6bn of medical devices and appliances prescribed in the community, we engaged with patient groups including commissioning National Voices to evidence the importance of lived experience in decision-making for products. 

We have just completed the first wave of products that have applied to remain listed on the tariff. This process included input from patient advocates to ensure expert panels factored lived experience into product assessment. We will shortly be publishing guidance on the disclosure of industry payments, following the Government’s response to the public consultation last year.

To develop the guidance, we brought together lead patient groups with industry trade associations and academia through a series of workshops to discuss key design principles. With support of the Patient Safety Commissioner, we have convened a quarterly patient forum bringing together over 70 patient groups and provide a platform for wider policy teams in the Department to flag new policy initiatives and invite input. If you are a patient group and are not already signed up to this forum, please reach out.

***MTG: Looking ahead to next year, what are your key priorities and what does success look like for you and your team; and what is the initiative that you are most looking forward to working on?***

DL: Translating policy priorities into practical action on the ground remains a key area of focus. An ABHI (Association of British Healthtech Industries) pulse survey earlier this year estimated the average lead time for the digital technology assessment criteria (DTAC) was over 12 weeks. If I was to choose one measure of success, bringing that down from months to days would be a demonstration of success that we are determined to deliver on.

I’m not allowed to have favourites! But the project that we are looking forward to seeing how it develops is a new partnership with the social enterprise, Rebuilding Futures Alliance. We are funding a programme in which the Rebuilding Futures Alliance (RFA) will support medtech companies recruit ex-offenders and those vulnerable to offending into roles in which companies struggle to recruit into.

This supports industry by reducing recruitment costs and delivers a huge social value benefit by reducing risk of reoffending and providing a life changing opportunity for arguably some of the most vulnerable members of society. RFA screens candidates and provides ongoing mentor support and data analysis to evidence social value impact.

---

*The MTG meets with David Lawson throughout the year to discuss progress on medical technology policy across the NHS. If you would like to be involved in these meetings as a member please* [*contact us.*](https://mtg.org.uk/contact-us/?ref=med-techinsights.com)